Zanubrutinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Zanubrutinib and local guidelines before prescribing.
BTK inhibitor
Mechanism
Bruton tyrosine kinase inhibitor.
Uses
CLL, mantle cell lymphoma, Waldenstrom macroglobulinaemia.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Bleeding, neutropenia, infection, AF.
Interactions
CYP3A4 inhibitors.
Contraindications and cautions
Active bleeding
Monitoring
FBC
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Less AF than ibrutinib; hold around surgery.
More from the textbook: uses, cautions and other points
- Ibrutinib , acalabrutinib, zanubrutinib (BTK) | CLL, mantle cell lymphoma, Waldenström's | Atrial fibrillation , bleeding (care with anticoagulants), hypertension, infections; CYP3A4 interactions
Haematology: Anatomy Physiology and Pharmacology - BTK inhibitors - ibrutinib, acalabrutinib , zanubrutinib - continuous tablets. Side effects: AF , bleeding (caution with anticoagulants), hypertension, infections.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Treat only when symptomatic: BTK inhibitors (zanubrutinib, ibrutinib) or bendamustine-rituximab; plasmapheresis for hyperviscosity. Rituximab can cause an IgM "flare", so use with caution when IgM is very high.
Haematology: Myeloma and Lymphoma - BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) used for CLL and lymphoma cause a milder version of this effect - infections are common.
Clinical Immunology: Primary immunodeficiency - Ibrutinib / acalabrutinib / zanubrutinib | BTK inhibitors for CLL; AF, bleeding, hypertension, infections.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Relapse: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), venetoclax, CAR-T.
Haematology: Myeloma and Lymphoma - Ibrutinib / acalabrutinib / zanubrutinib | BTK inhibitors for mantle cell, Waldenström and CLL; atrial fibrillation, bleeding, hypertension, infections.
Haematology: Myeloma and Lymphoma - BTK inhibitors - ibrutinib, acalabrutinib, zanubrutinib (CLL, lymphoma) - bleeding, AF, hypertension, infections; remibrutinib (chronic urticaria - emerging).
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (2 mentions)
- Haematology: Myeloma and Lymphoma (3 mentions)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)